Quarterly Earnings

Early data for Sutro Biopharma's STRO-004 offers a glimmer of hope for advanced cancer patients. We look at the tech, the trials, and the financial tightrope.

With revenue up 23%, Rubicon Organics invests heavily in new facility tech, temporarily squeezing profits to fuel its bid for long-term global dominance.

Riskified reports its strongest growth in four years, raising its outlook. Our analysis digs past the headlines to the execution behind its AI platform.

Beyond a simple payout, Ituran's latest dividend reveals a robust financial engine, savvy tax strategy, and a deep-seated plan to dominate the future of mobility.

Local Bounti posts 14% revenue growth and narrows losses, but a deep dive into its Q2 financials reveals the high-stakes reality of its path to profitability.

Ituran's stellar Q2 results aren't just about the numbers. They reveal a strategic pivot from vehicle recovery to a diversified, data-driven mobility platform.

Tencent's latest earnings reveal a shocking negative cash flow, driven by a 176% surge in spending. It's a high-stakes gamble on AI to redefine its future.

Beyond record profits, Nykredit's H1 results reveal a powerful strategy. Its customer-owned model and bold M&A are reshaping Danish finance. But is it sustainable?

Computer Modelling Group reports a 60% profit drop after a major client loss, yet initiates a $20M share buyback. A sign of confidence or a risky gamble?

Cavvy Energy's stunning Q2 results are more than a commodity boom. A closer look reveals a story of strategic resilience and a powerful midstream pivot.

COSCIENS Biopharma boasts a dramatic financial turnaround, but its strategic move to exit SEC oversight shifts the risk-reward calculus for investors.

Reed's Q2 results show major operational gains and a shrinking net loss, but a steep sales decline and a looming cash crunch raise critical questions.

With a NYSE delisting notice and a dividend under scrutiny, Lument Finance Trust's Q2 report is more than just numbers—it's a test of its strategy.

With FDA clearance for its AI burn scanner, Spectral AI faces its next test: conquering the market. Can it turn government contracts into commercial success?

With pivotal data imminent for two cancer drugs and a fortified balance sheet, SELLAS is at a crucial inflection point. Can it deliver on its promise?

NeuroPace reports strong Q2 growth and raises 2026 guidance, driven by its RNS system. A new AI tool and key clinical data signal a deeper push into personalized medicine.

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.

Black Rock Coffee Bar reports a stellar quarter with 25% revenue growth, but a deeper look reveals the complex challenges of rapid expansion in a competitive market.

AGT Food and Ingredients' Q2 results signal a successful shift to higher-margin foods, with its packaged foods segment surging despite global headwinds.

A sharp revenue drop and net loss for IZEA masks a major strategic pivot. With $46M in cash, the company is betting its future on enterprise clients.